Revolution Medicines, Inc.
RVMD
Classifica tra le azioni
#581
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Prezzo delle azioni
$196.16
Ultima sincronizzazione: 2026-10-20
Capitalizzazione di mercato
$42.04B
Variazione (1 giorno)
7.69%
Variazione (1 anno)
266.72%
Paese
US
Scambia Revolution Medicines, Inc. (RVMD)
Categoria
Healthcare
Ricavi di Revolution Medicines, Inc. (RVMD)
Ricavi nel Jun 2026 TTM: 0.00
Secondo gli ultimi rapporti finanziari di Revolution Medicines, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0.00. Nel 2023, l'azienda ha registrato ricavi di $11.58M una diminuzione rispetto a i ricavi dell'anno 2022, che erano pari a $35.38M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Revolution Medicines, Inc. da 2017 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | -100.00% |
| 2023 | $11.58M | -67.27% |
| 2022 | $35.38M | 20.38% |
| 2021 | $29.39M | -31.62% |
| 2020 | $42.98M | -14.10% |
| 2019 | $50.04M | 148.16% |
| 2018 | $20.17M | 0.00% |
| 2017 | 0.00 | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| - | - |
CH
|
|
| $6.02B | - |
NL
|
